| 1 Number of patients with positive HVC‐RNA level at end of treatment |
1 |
26 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.42, 1.74] |
| 2 Number of patients with positive HCV‐RNA level 26 weeks after treatment |
1 |
38 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.52, 1.38] |
| 2.1 Short‐term pre‐treatment with glucocorticosteroids followed by interferon |
1 |
38 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.52, 1.38] |
| 2.2 Long‐term treatment with glucocorticosteroids in parallel with interferon |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 3 Number of patients without normalisation of ALT at end of treatment |
5 |
307 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.77, 1.11] |
| 3.1 Short‐term pre‐treatment with glucocorticosteroids followed by interferon |
4 |
281 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.74, 1.08] |
| 3.2 Long‐term treatment with glucocorticosteroids in parallel with interferon |
1 |
26 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.69, 2.39] |
| 4 Number of patients without normalisation of ALT 24 to 26 weeks after treatment |
5 |
307 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.84, 1.06] |
| 4.1 Short‐term pre‐treatment with glucocorticosteroids followed by interferon |
4 |
281 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.83, 1.05] |
| 4.2 Long‐term treatment with glucocorticosteroids in parallel with interferon |
1 |
26 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.64, 1.97] |
| 5 Liver histology (patients without decrease in necroinflammatory activity at end of treatment) |
1 |
26 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.38 [0.13, 1.11] |
| 6 Liver histology (patients without decrease in necroinflammatory activity at end of follow‐up (26 weeks). |
1 |
26 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.78 [0.57, 1.07] |
| 7 Serious adverse events |
6 |
342 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.76 [0.24, 93.19] |
| 7.1 Short‐term pre‐treatment with glucocorticosteroids followed by interferon |
4 |
281 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.76 [0.24, 93.19] |
| 7.2 Long‐term treatment with glucocorticosteroids in parallel with interferon |
2 |
61 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 8 Adverse events |
3 |
320 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.71, 1.43] |
| 8.1 Fever |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.44, 2.39] |
| 8.2 Myalgia |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.36, 3.37] |
| 8.3 headache |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.27, 2.93] |
| 8.4 Alopecia |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.06, 12.91] |
| 8.5 Depression |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.27, 2.93] |
| 8.6 Fatigue |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.56, 2.29] |
| 8.7 Nausea |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.09 [0.75, 12.65] |
| 8.8 Irritability |
1 |
32 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [0.40, 2.77] |
| 8.9 Flu‐like syndrome |
1 |
26 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.14 [0.02, 1.00] |
| 8.10 Sleep disturbance |
1 |
38 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.13, 69.31] |
